Illumina, Inc. (NASDAQ:ILMN) Given Consensus Rating of “Hold” by Brokerages

Illumina, Inc. (NASDAQ:ILMN) has earned a consensus rating of “Hold” from the seventeen ratings firms that are covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $188.40.

A number of research firms have recently weighed in on ILMN. Wall Street Zen upgraded Illumina from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. Weiss Ratings upgraded shares of Illumina from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, June 3rd. Leerink Partners boosted their price objective on shares of Illumina from $175.00 to $210.00 and gave the company an “outperform” rating in a report on Friday, July 17th. Stifel Nicolaus upped their target price on shares of Illumina from $155.00 to $225.00 and gave the company a “buy” rating in a research report on Friday, July 31st. Finally, JPMorgan Chase & Co. increased their target price on shares of Illumina from $220.00 to $230.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st.

Illumina Stock Up 1.7%

ILMN stock opened at $223.22 on Tuesday. Illumina has a one year low of $88.00 and a one year high of $223.97. The firm has a market cap of $33.71 billion, a PE ratio of 41.65, a PEG ratio of 3.09 and a beta of 1.44. The firm’s 50 day moving average price is $189.13 and its 200-day moving average price is $153.14. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The company had revenue of $1.16 billion during the quarter, compared to analyst estimates of $1.13 billion. During the same period in the prior year, the business posted $1.19 earnings per share. The firm’s revenue for the quarter was up 9.4% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, equities research analysts anticipate that Illumina will post 5.36 EPS for the current year.

Insider Transactions at Illumina

In related news, CAO Scott D. Ericksen sold 1,500 shares of Illumina stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $150.10, for a total value of $225,150.00. Following the completion of the sale, the chief accounting officer owned 14,946 shares in the company, valued at approximately $2,243,394.60. This trade represents a 9.12% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Christensen Jakob Wedel sold 1,033 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $191.52, for a total value of $197,840.16. Following the completion of the sale, the senior vice president directly owned 14,023 shares in the company, valued at approximately $2,685,684.96. The trade was a 6.86% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 2,095,958 shares of company stock worth $401,720,974. 2.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Illumina

Institutional investors have recently modified their holdings of the company. BlackRock Inc. acquired a new stake in Illumina during the 2nd quarter worth approximately $3,374,423,000. Plato Investment Management Ltd acquired a new position in shares of Illumina in the second quarter worth $948,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of Illumina in the second quarter worth $30,501,000. Edmond DE Rothschild Holding S.A. purchased a new stake in shares of Illumina during the second quarter worth $129,792,000. Finally, Impact Partnership Wealth LLC increased its position in shares of Illumina by 235.8% during the first quarter. Impact Partnership Wealth LLC now owns 11,080 shares of the life sciences company’s stock worth $1,366,000 after acquiring an additional 7,780 shares during the period. 89.42% of the stock is owned by institutional investors and hedge funds.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.